BIOL (BIOLASE) Net Profit

Corporate emblem and logo of biolase.com (BIOL)

Electronics supplier diversification ensures supply chain resilience and stable margins for BIOLASE, Inc. (BIOL). The company's reported earnings help identify business inflection points, with the -0.04 mark serving as a key metric. Revenues are based on regular service and the sale of consumables. High product quality is maintained through scheduled upgrades of assembly lines and precise calibration of emitters.

BIOL: BIOLASE, Inc. Net Profit 07/04/2022 - 08/04/2024

Financial and market metric breakdowns for BIOLASE (BIOL)

- current quotes and average value forecast:
Market Chart Biolase Inc.|BIOL - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Biolase Inc.|BIOL - Total Company Value
- book capitalization data:
Net Assets per Single Share BIOLASE|BIOL - Book Capitalization|Market Capitalization to Book Value biolase.com|BIOL - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Equity BIOLASE, Inc.|BIOL - Long-Term Debt to Capital|Current Liabilities to Capital BIOLASE Inc.|BIOL - Company Aggregate Debts|Debt to Book Value Ratio Biolase Inc.|BIOL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings BIOLASE|Quick Liquidity Indicator biolase.com
- earnings and valuation multiples information:
BIOL - Net Profit
Fundamental valuation:Biolase Inc.
Product sample of BIOLASE, Inc.

BIOLASE, Inc. (BIOL) dependence on external precision optics suppliers directly impacts the company's bottom line, where any component logistics disruptions immediately erode operating margins. This indicator measures the net remaining funds after all expenses, allowing investors to filter out market noise and assess the business's actual ability to generate sustainable capital.

Key competitors

BSX - Net Financial Result|EW (Edwards Lifesciences) - Net Profit|Net Profit resmed.com|Company Net Income Insulet (PODD)|Company Net Income ZBH (Zimmer Biomet Holdings)|Net Profit COO (CooperVision)|Net Financial Result Align Corp (ALGN)|GMED: Net Income|Profit After Tax TMDX|ATEC: Net Profit|Company Net Income CryoLife (AORT)|ENOV (DJO Global) - Net Profit|Company Profit IART (Integra LifeSciences Inc.)|Net Income ESTA (Establishment Labs)|BBNX (betabionics.com) - Final Profit|Company Net Income IRADIMED IRMD|EMBC - Net Income|Tandem Diabetes - Net Profit|Company Net Income Axogen Surgical|SIBN: Net Profit|Company Profit OFIX|BVS (Bioventus) - Net Profit|OrthoPediatrics Inc. (KIDS) - Net Financial Result|Net Profit TMCI|Net Income Strata Medical SRTA|Net Profit CARL (Carlsmed Inc)|Net Profit rxsight.com RXST|CLPT - Company Net Income|STXS: Company Net Income|STIM (NeuroStar) - Net Income|Sight Sciences Inc - Final Profit|OBIO (Orchestra BioMed) - Net Profit|Company Net Income Anika ANIK|Company Net Income InspireMD (NSPR)|zhjmedical.com (ZJYL) - Annual Net Income|Vivani Medical - Net Income|Net Profit Xtant Medical Holdings, Inc. XTNT|NeuroOne Medical Technologies - Net Profit|Net Financial Result Modular Medical MODD|Myomo (MYO) - Company Net Income|Profit After Tax COCH (Envoy Medical Inc.)|Company Net Income Vivos Therapeutics, Inc|Net Income enVVeno Corp (NVNO)|Net Profit SINT|TNON - Company Net Income|Company Net Income Lifeward LFWD|AMIX: Company Profit|IVF: Net Income|Bone Biologics Inc - Profit After Payment of Taxes|AXNX: Net Profit|DYNT (Dynatronics) - Company Net Income|FNA (Paragon 28 Inc.) - Net Profit|INVO Bio (INVO) - Net Financial Result